1、$Five Prime(FPRX)$\$Pandion Therapeutics(PAND)相继被并购,可否燃起医药板块的热情?
2、$Talis Biomedical(TLIS)$ 新股破发,是否有配置价值?
$快手-W(01024)$查看全文
chuminhua2021-03-04 23:29
3月4日,安进(Amgen)宣布将以19亿美元收购Five Prime。Five Prime的核心产品为FGFR2b抗体bemarituzumab等。再鼎医药于2017年以500万美元预付款+3900万美元里程碑金额引进Bemarituzumab的大中华区权益。$安进(AMGN)$ $Five Prime(FPRX)$查看全文
产业链观察2021-03-04 22:35
药闻| 2021年3月4日,- $安进(AMGN)$ 和$Five Prime(FPRX)$ (一家临床阶段的生物技术公司,专注于开发免疫肿瘤以及针对性癌症疗法),今天宣布了一项协议,安进公司将以每股38.00美元的现金价格收购Five Prime Therapeutics ,相当于约19亿美元的股权价值。
此次收购将Five Prime的创新产品线添...查看全文
Replix锐璞美股2021-03-04 22:03
$Five Prime(FPRX)$ 被收购!
Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime ...查看全文
chuminhua2020-11-12 22:14
Five Prime Therapeutics日前宣布,其“first-in-class”靶向FGFR2b的单克隆抗体疗法bemarituzumab(FPA144),与化疗联用,在一线治疗晚期胃癌或胃食管连接部(GEJ)癌患者的2期临床试验中获得积极结果。这些患者的肿瘤为FGFR2b阳性,HER2阴性。新闻稿指出,这是首个表明针对FGFR2b的靶向治疗可能...查看全文
$Five Prime(FPRX)$ 8-K - Current report Filed: 2019-01-07 AccNo: 0001193125-19-003022 Size: 18 KBItem 2.02: Results of Operations and Financial ConditionItem 7.01: Regulation FD Disclosure 网页链接
$Five Prime(FPRX)$ CT ORDER - Confidential treatment order Filed: 2018-12-19 AccNo: 9999999997-18-009608 Size: 93 KB 网页链接
$Five Prime Therapeutics, Inc.(FPRX)$ CT ORDER - Confidential treatment order Filed: 2018-12-19 AccNo: 9999999997-18-009608 Size: 93 KB 网页链接
$Five Prime Therapeutics, Inc.(FPRX)$ 8-K - Current report Filed: 2018-11-29 AccNo: 0001193125-18-338035 Size: 26 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem...
$Five Prime Therapeutics, Inc.(FPRX)$ 内部交易: 2018-11-05,执行Chairman,Williams Lewis T ,期权,91217普通股, $4.56
$Five Prime Therapeutics, Inc.(FPRX)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-11-06 AccNo: 0001564590-18-027433 Size: 6 MB 网页链接
$Five Prime Therapeutics, Inc.(FPRX)$ S-3 - Registration statement under Securities Act of 1933 Filed: 2018-11-06 AccNo: 0001193125-18-319597 Size: 219 KB 网页链接
$Five Prime Therapeutics, Inc.(FPRX)$ 8-K - Current report Filed: 2018-11-06 AccNo: 0001193125-18-319572 Size: 83 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Five Prime Therapeutics, Inc.(FPRX)$ 8-K - Current report Filed: 2018-11-05 AccNo: 0001193125-18-317874 Size: 35 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem...
$Five Prime Therapeutics, Inc.(FPRX)$ 8-K - Current report Filed: 2018-11-05 AccNo: 0001193125-18-317874 Size: 35 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem...